Christine Hafner Selected Research

Antibodies

5/2023	Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
1/2021	The Major Peanut Allergen Ara h 2 Produced in Nicotiana benthamiana Contains Hydroxyprolines and Is a Viable Alternative to the E. Coli Product in Allergy Diagnosis.
1/2019	Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.
7/2015	Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
12/2008	Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine.
7/2005	High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christine Hafner Research Topics

Disease

17	Melanoma (Melanoma, Malignant) 12/2023 - 10/2002
12	Neoplasms (Cancer) 12/2023 - 01/2005
12	Hypersensitivity (Allergy) 01/2023 - 01/2011
6	Peanut Hypersensitivity (Peanut Allergy) 01/2021 - 07/2013
3	Seasonal Allergic Rhinitis (Hay Fever) 08/2022 - 01/2015
2	Leukemia 11/2022 - 01/2017
2	Neoplasm Metastasis (Metastasis) 09/2022 - 01/2016
2	Hypoxia (Hypoxemia) 04/2016 - 07/2015
1	Skin Neoplasms (Skin Cancer) 05/2023
1	Hepatocellular Carcinoma (Hepatoma) 10/2022
1	Brain Neoplasms (Brain Tumor) 09/2022
1	Hemorrhage 09/2022
1	Breast Neoplasms (Breast Cancer) 09/2021
1	Glioma (Gliomas) 09/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2021
1	Anaphylaxis (Anaphylactic Shock) 01/2020
1	Blister (Bulla) 01/2019
1	Latex Hypersensitivity (Latex Allergy) 01/2011

Drug/Important Bio-Agent (IBA)

12	Immunoglobulin E (IgE)IBA 01/2023 - 01/2011
8	AllergensIBA 08/2022 - 01/2011
7	Proteins (Proteins, Gene)FDA Link 09/2023 - 04/2005
6	AntibodiesIBA 05/2023 - 07/2005
5	EpitopesIBA 01/2020 - 10/2002
5	VaccinesIBA 01/2017 - 01/2005
5	HMW-MAAIBA 12/2008 - 01/2005
4	ParvalbuminsIBA 12/2022 - 01/2015
4	Phosphotransferases (Kinase)IBA 10/2022 - 07/2015
4	hypoxanthine arabinoside (ara-H)IBA 01/2020 - 07/2013
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2023 - 01/2017
3	VemurafenibIBA 09/2021 - 07/2015
3	Monoclonal AntibodiesIBA 09/2021 - 10/2002
3	Indicators and Reagents (Reagents)IBA 10/2016 - 04/2005
2	Neoplasm Antigens (Tumor Antigens)IBA 09/2023 - 07/2015
2	chondroitin sulfate proteoglycan 4IBA 09/2023 - 07/2015
2	LeguminsIBA 08/2022 - 01/2021
2	Chondroitin Sulfate ProteoglycansIBA 09/2021 - 07/2015
2	Chondroitin Sulfates (Chondroitin Sulfate)IBA 09/2021 - 01/2021
2	Messenger RNA (mRNA)IBA 01/2021 - 07/2015
2	Carbonic Anhydrase IXIBA 04/2016 - 07/2015
2	Immunoglobulin G (IgG)IBA 07/2013 - 12/2008
2	Peptides (Polypeptides)IBA 04/2005 - 10/2002
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2023
1	trametinibIBA 12/2023
1	dabrafenibIBA 12/2023
1	NivolumabIBA 05/2023
1	pembrolizumabIBA 05/2023
1	CarbohydratesIBA 11/2022
1	Sorafenib (BAY 43-9006)FDA Link 10/2022
1	Melanins (Melanin)IBA 09/2022
1	HemosiderinIBA 09/2022
1	AcidsIBA 09/2022
1	talimogene laherparepvecIBA 01/2021
1	Proteoglycans (Proteoglycan)IBA 01/2021
1	Interleukin-3 (Interleukin 3)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2017
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2017
1	Protein Kinases (Protein Kinase)IBA 04/2016
1	Janus KinasesIBA 04/2016
1	Cadherins (E-Cadherin)IBA 01/2016
1	tyrosine receptor (receptor, tyrosine)IBA 07/2015
1	CalciumIBA 01/2015
1	heveinIBA 01/2011
1	LatexIBA 01/2011
1	ChitinasesIBA 01/2011
1	AntigensIBA 04/2005
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 10/2002

Therapy/Procedure

6	Therapeutics 05/2023 - 04/2005
4	Immunotherapy 01/2020 - 01/2005
1	Injections 01/2021
1	Subcutaneous Injections 04/2005
1	Drug Therapy (Chemotherapy) 01/2005
1	Radiotherapy 01/2005